

REFERENCES

1. ASHP. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. *Am J Hosp Pharm.* 1985;42:131-7.
2. ASHP. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. *Am J Hosp Pharm.* 1990;47:1033-49.
3. ASHP. ASHP guidelines on handling hazardous drugs. *Am J Health-Syst Pharm.* 2006;63:1172-93.
4. Centers for Disease Control and Prevention. NIOSH Alert on *Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings*, 2004. Publication number 2004-165. <http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf>. Accessed 25 September 2016.
5. NIOSH List of *Antineoplastic and Other Hazardous Drugs in Healthcare Settings*, 2016. Publication number 2016-161. <http://www.cdc.gov/niosh/docs/2014-138/pdfs/2016-161/pdf>. Accessed 25 September 2016.
6. Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. https://www.osha.gov/SLTC/hazardousdrugs/controlling_occeh_hazardousdrugs.html. Accessed 25 September 2016.
7. Occupational exposure to antineoplastics and other hazardous drugs, <http://www.cdc.gov/niosh/topics/antineoplastic/default.html>. Accessed 25 September 2016.
8. United States Pharmacopeial Convention. General chapter <800> hazardous drugs—handling in healthcare settings. *USP 40-NF 35*; 2017.
9. Centers for Medicare & Medicaid Services, State Operations Manual, Appendix A—Survey Protocol, Regulations and Interpretive Guidelines for Hospitals. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107ap_a_hospitals.pdf. Accessed 25 September 2016.
10. Centers for Disease Control and Prevention. NIOSH Workplace Solutions, *Medical Surveillance for Health Care Workers Exposed to Hazardous Drugs*, 2007. Publication number 2013-103. <http://www.cdc.gov/niosh/docs/wp-solutions/2013-103/pdfs/2013-103.pdf>. Accessed 19 May 2016.
11. Polovich M. *Safe Handling of Hazardous Drugs*, 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011.
12. Murdaugh LB. *Competence Assessment Tools for Health-System Pharmacies*, 5th ed. Bethesda, MD: ASHP; 2015.
13. Centers for Disease Control and Prevention. NIOSH Workplace Solutions, *Personal Protective Equipment for Health Care Workers Who Work with Hazardous Drugs*, 2008. Publication number 2009-106. <http://www.cdc.gov/niosh/docs/wp-solutions/2009-106/pdfs/2009-106.pdf>. Accessed 25 September 2016.
14. ASTM D6978-05 (2013). Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs. West Conshohocken, PA: ASTM International.
15. ASTM F739-99a. Standard Test Method for Resistance of Protective Clothing Materials to Permeation by Liquids or Gases under Conditions of Continuous Contact. West Conshohocken, PA: ASTM International.
16. NSF/ANSI 49-2004. Class II (laminar flow) Biosafety Cabinetry, NSF International. Ann Arbor, MI 48113-0140. www.nsf.org
17. CETA International, Application Guide for Sterile Compounding Facilities CAG-003-2006 (Revised May 2015). www.cetainternational.org/ceta-application-guides-for-nonmembers. Accessed 25 September 2016.
18. United States Pharmacopeial Convention. General chapter <797> pharmaceutical compounding—sterile preparations. *USP 40-NF 35*; 2017.
19. Critical Point Pearls of Knowledge archive. <https://www.criticalpoint.info/tools-resources/sterilecompounding-pearls/>. Accessed 25 September 2016.
20. JCR Hazardous Drug Toolkit. www.hazmedsafety.com. Accessed 12 March 2017.
21. United States Pharmacopeial Convention. General chapter <795> pharmaceutical compounding—nonsterile preparations. *USP 40-NF 35*; 2017.
22. United States Pharmacopeial Convention. Proposed revisions to general chapter <797> pharmaceutical compounding—sterile preparations. http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/usp-gc-797-proposed-revisions-sep-2015.pdf. Accessed 12 March 2017.